



*International Conference on*  
***Alzheimer's Disease and Dementia***

*Theme: - Resilience in Alzheimer's disease and Dementia*

**March 09-10, 2020**

**Lisbon, Portugal**

[contact@alzheimersconferences.org](mailto:contact@alzheimersconferences.org)

## *Invitation:*

Cenetri Publishing Group takes keen delectation and highly regarded to host a Captivating Scientific meeting “International Conference on Alzheimer’s Disease and Dementia”. The Conference highlights the theme “Resilience in Alzheimer’s disease and Dementia” March 09-10, 2020 Lisbon, Portugal. International Conference on Alzheimer’s Disease and Dementia presents a unique occasion to meet prominent Directors, Neurologist, Neurosurgeons, doctors, academician, scientists and specialists across the globe and listen to best speakers on new expansions that will influence and spread the future of Alzheimer’s Disease and Dementia. The conference will unite the endeavors made all over the world to spread the field of Health through speakers and suppliers who are recognized world leaders in this area of specialization.

## *About Conference:*

Cenetri Conferences organizing the Dementia 2019 which is going to be held from March 09-10, 2020 in Lisbon, Portugal focusing on current and future advancements in Alzheimer’s Disease and Dementia. The theme of this year’s meeting is “Resilience in Alzheimer’s disease and Dementia”, which will provide an international platform for discussion and sharing of novel ideas for present and future expansions in various fields of Neuroscience such as Alzheimer’s Disease and Dementia, Aging, Neurological disorders, Parkinson’s, Neuroimaging, Cognitive neuroscience and expertise meeting. World-leading health practitioners, clinicians, educators and researchers will present cutting-edge and practical clinical techniques based upon widely accepted evidence and will introduce new and innovative research.

## *Conference Highlights*

- 9+ Keynote Speakers
- 30+ Plenary Speakers
- 3+ Exhibitors
- 14 Innovative Educational Sessions
- B2B Meetings
- Exhibition



## *Why to attend???*

International Conference on Alzheimer's Disease and Dementia is a unique forum to bring together worldwide distinguished academics in the field of neuroscience and neurology, Brain researchers, public health professionals, scientists, academic scientists, industry researchers, scholars to exchange about state of the art research and technologies. Aim of this conference is stimulate new ideas for treatment that will be beneficial across the spectrum of Alzheimer's.

- Gathering of world class researchers and budding talent from across the globe.
- Showcase your research and get world recognition.
- Avail chances to interact with world renowned scientists.
- Perfectly designed schedule: Workshop, Expo areas, brainstorming sessions and many more. Platform to network with fellow primary care clinicians.
- Educational workshops on diagnosis and treatment of neurological diseases.



## *Target Audience:*

- Directors
- Neurologist
- Neurosurgeons
- Psychiatrist
- Head of the department
- Professors and Students from academia and researchers in the field of Neurosciences

## *Sessions/Tracks*

- Alzheimer's Disease
- Alzheimer's Disease and Cellular Mechanism
- Medical Biotechnology and Alzheimer's Disease
- Mild Alzheimer's disease
- Diagnostic Alzheimer's
- Dementia Care
- Vascular Dementia
- Traumatic Brain Injury
- Dementia with Lewy Bodies
- Managing Dementia
- Memory loss and other symptoms of dementia
- Aging and Gerontology
- Amyloid Protein in Dementia
- Childhood Trauma and Dementia
- Dementia Nursing:
- Dementia Care and Consulting
- Diagnostic Alzheimer's
- Molecular Genetics and Biology of Dementia
- Managing Behavior
- Diagnosis of dementia
- Dementia treatment and care
- Dementia risk and prevention




## Market Analysis:

The global Alzheimer's therapeutics market was valued at USD 4.0 billion in 2015 owing to the increasing prevalence and incidence rates of this disease and growing geriatric population base.

In 2015, it was estimated that 47 million people were living with Alzheimer's Disease (AD) across the globe. It mostly occurs in the older people who are 65 years and above. Moreover, growing awareness level regarding its symptoms, such as partial dementia, is projected to boost the demand.

The development of new and innovative technologies is expected to contribute to the growth of the overall market. For instance, the development of new cloud-based cognitive assessment systems is expected to propel the growth. These systems help in identification of effects of drugs in patients. Hence, with the help of this system, pharmaceutical companies can evaluate the efficacy and safety of pipeline drugs for the treatment of this disease.



# *Market Synopsis of Global Alzheimer's Disease Diagnostic Market:*

## *Market Scenario:*

Alzheimer's is a type of dementia which results in memory loss accompanied by problem in thinking and behavior process. Alzheimer's is a progressive disease as it gradually increases with time and damages maximum part of the brain finally destroying brain cells. It has been observed that maximum incidence of this disease is in UK where more than 520,000 people are diagnosed with Alzheimer's disease and the increasing ageing population is the reason which is driving Alzheimer's disease diagnostic and therapeutic market.

The Global Alzheimer's Disease Diagnostic Market for this is expected to reach USD 12 billion by the end of the forecasted period growing at a CAGR of 10%.

## *Scope of the Report:*

This report focuses on the Alzheimer's Disease Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

In the last several years, global market of alzheimer's disease drug change huge.

The classification of alzheimer's disease drug includes Memantine, Donepezil, Rivastigmine and Others, and the proportion of Memantine in 2018 is about 49.28%. The market for Donepezil, is decrease quickly in past five years.

Alzheimer's disease drug are widely used for Early to Moderate, Moderate to Severe stage treatment. The most proportion of alzheimer's disease drug used to Moderate to Severe, and the market share in 2018 is 55.82%.

The worldwide market for Alzheimer's Disease Drug is expected to grow at a CAGR of roughly -11.3% over the next five years, will reach 1580 million US\$ in 2023, from 2870 million US\$ in 2018, according to a new GIR (Global Info Research) study.

## *Major Alzheimer's Associations:*

- Alzheimer's Association
- National Health Council
- Alzheimer's Foundation of America
- Global Alzheimer's Association
- Alzheimer Society of Canada
- Alzheimer's Los Angeles

- Alzheimer Society of Ireland
- National Institute on Aging–Alzheimer's Association
- United Corpus Christi Alzheimer's Association
- Cyprus Alzheimer's Association
- Alzheimer's Association Illinois
- Alzheimer's Association of Kenya
- Alzheimer's Association of Trinidad and Tobago

## *About Lisbon*

Lisbon is the capital and the largest city of Portugal, with an estimated population of 505,526 within its administrative limits in an area of 100.05 km. Its urban area extends beyond the city's administrative limits with a population of around 2.8 million people, being the 11th-most populous urban area in the European Union. About 3 million people live in the Lisbon Metropolitan Area (which represents approximately 27% of the country's population). It is mainland Europe's westernmost capital city and the only one along the Atlantic coast. Lisbon lies in the western Iberian Peninsula on the Atlantic Ocean and the River Tagus. The westernmost areas of its metro area form the westernmost point of Continental Europe, which is known as Cabo da Roca, located in the Sintra Mountains.

## *Contact:*

**Conference Convenor**

**Thinish R**

[contact@alzheimersconferences.org](mailto:contact@alzheimersconferences.org)

Phone +1 302-549-2191

